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ond-order approach. RESULTS: Clinical success was 75.63% on tigecicline group,
41.45% on ceftriaxone/metronidazole group and 72.80% on ertapenem group. Cost
per patient was always lower with tigecicline ($69,277.63USD) than ertapenem
($73,177.39USD) or ceftriaxone/metronidazole ($211,513.05USD) due lower hospital
length of stay and complications; then tigecicline was the cost-saving alternative.
The sensitivity analyses show the robustness of the model confirming tigecycline
as the dominant alternative. CONCLUSIONS: Results show that tigecicline is cost-
saving in the treatment of complicated intra-abdominal infections in Mexico and
should be considered by clinicians and decision makers as a favorable option for
this kind of infections.
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OBJECTIVES: In Canada, a 13-valent conjugate polysaccharide pneumococcal vac-
cine (PCV13) has recently been licensed for immunocompetent adults aged 50 years
or older, as well as children over the age of 5. Currently, a 23-valent pneumococcal
polysaccharide vaccine (PPV23) is recommended for high risk adults and all se-
niors. The health benefits and economic value of vaccinating Canadian adults with
PCV 13 instead of PPV 23 is unknown. Compared to PCV13, PPV 23 covers 11 addi-
tional serotypes but may not be as effective for the 12 shared serotypes due to
PCV13 being a conjugate vaccine as opposed to a polysaccharide. The objective is to
develop amodel that compares the health and economic consequences of PCV13 as
compared to PPV23 in Canadian adults aged 50.METHODS:We developed a base
simulationmodel for an entire population of providing PCV13 to children less than
2 years of age and simulating the herd effects to the greater population. Vaccinat-
ing adults older than 50 years of agewith either PCV13 or PPV23was then compared
to the base model, and the health and economic consequences examined across
each scenario. Health impacts included invasive pneumococcal disease and pneu-
mococcal related disease. Invasive disease is caused by Streptococcus Pneumococ-
cal and is clinically presented as: meningitis, bacteremia and invasive pneumonia.
Pneumococcal related disease is non invasive and has many different etiologies,
the main clinical presentations include: otitis media (in base model for children
only), and non-invasive pneumonia. Costs and QALYs were contrasted between
the two adult vaccination strategies. RESULTS: Compared to PPV23, PCV13 was
associated with 0.278more cases of invasive pneumonia, 0.061more cases of bac-
teremia, 0.002more cases of meningitis, and 27.997less cases of pneumococcal
related disease per 100,000. Compared to PPV23, the incremental cost effectiveness
ratio associated with PCV13 was $10,028 per additional QALY gained.
CONCLUSIONS: Compared to PPV23, vaccinating adults with PCV13 is cost effec-
tive.
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OBJECTIVES:Vaccination is an effectivemethod to reducemortality andmorbidity
from pneumococcal disease. Three pneumococcal conjugate vaccines (PCVs) are
currently available with varying serotype coverage (PCV-7, PCV-10, and PCV-13),
therefore it is necessary to carefully evaluate and compare their potential public
health and economic impacts before implementation. This study aims to estimate
the cost-effectiveness of immunization strategies based on the PCVs currently
available on the Ecuadorian market from a societal perspective. METHODS: A de-
cision tree model was implemented to estimate the public health and economic
impact of PCV use in a cohort of children younger than two years of age (lifetime
horizon, discount rate: 3% annual). Alternatives strategies included: no vaccination
(reference case) versus 7, 10, and 13 valent PCV=s. The measures of effectiveness
considered were: deaths avoided, life years gained (LYG) and quality adjusted life
years (QALY=s) gained. Effectiveness, utility, local epidemiology and cost of treating
pneumococcal diseaseswere extracted frompublished sources and gray literature.
RESULTS: All three immunization alternatives dominate the no vaccination sce-
nario. Compared to no vaccination, PCV-13 is estimated to prevent 986 deaths,
saving 29,410 LY=s and 26,852 QALY=s. This strategy represented cost savings of
$550 per vaccinated child. The other two vaccination alternatives, PCV-7 and PCV-
10, prevented 537 and 940 deaths; saved 15,865 and 28,129 LY=s; saved 14,584 and
25,662 QALY=s; and saved $255 and $527 per vaccinated child, respectively. These
results are robust to variations in herd immunity, but sensitive to the prices of the
vaccine per dose and the number of doses. CONCLUSIONS: In Ecuador, immuniza-
tion strategies based on PCV 7, 10, and 13 valent vaccines would be cost saving
interventions compared to no vaccination. The PCV-13 valent strategy dominates
in terms of cost-effectiveness and cost-utility to PCV 7 and PCV10.
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OBJECTIVES: This study compared the costs and effectiveness of fidaxomicin and
vancomycin for the treatment of Clostridium difficile infection (CDI). This analysis
was conducted from a hospital perspective to assist health-care providers in de-
ciding whether to add fidaxomicin to their formularies.METHODS: A decision tree
model examined whether fidaxomicin or vancomycin is more cost-effective for
treating CDI. Outcomes data for this analysis were obtained from OPT-80-003 Clin-
ical Study Group (fidaxomicin versus vancomycin) clinical trial. The main out-
comes were: clinical cure which is resolution of symptoms, recurrence of CDI, and
global cure which is clinical cure with no recurrence. Cost data were per CDI pa-
tient: 10 days hospitalization costs ($17,196), 10 days fidaxomicin regimen costs
($2,800), and 10 days vancomycin regimen costs ($26.8). RESULTS: The baseline
cost effectiveness analysis found that fidaxomicin was slightly more effective but
more costly than vancomycin. That means that a hospital would pay an extra
$31,539 if fidaxomicin were chosen to treat each episode of CDI. Themodel is most
sensitive to hospitalization costs, which is coherent with the literature. A one-way
sensitivity analysis on drug cost found that fidaxomicin did not dominatewhatever
the costwas. A two-way sensitivity analysis on hospitalization cost and the clinical
cure rate of fidaxomicin found that vancomycin was only dominated when fidax-
omicin cure rates reached 97%, and this is highly unlikely. CONCLUSIONS: Based
upon this analysis, vancomycin is the recommended drug of choice for CDI treat-
ment. The hospital would pay an extra $31,539 to treat each episode of CDI using
fidaxomicin. Fidaxomicin would only be preferred if it had a higher clinical cure
rate and a cheaper price according to the sensitivity analysis. As a conclusion,
hospitals could consider fidaxomicin as second line treatment for cases in which
patients have failed a course of treatment with vancomycin.
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OBJECTIVES: Invasive pulmonary aspergillosis (IPA) is a disease that affects immu-
nocompromised patients and is the major cause of death related to infections in
patients with acute leukemia and recipients of bone marrow transplant. Further-
more, is also themost prevalent within the spectrum of invasive aspergillosis. The
aim of this study was to perform a cost-effectiveness analysis of voriconazole
compared to amphotericin B deoxycholate in the treatment of IPA in immunocom-
promised adults’ patients in Colombia from the third-party payer perspective.
METHODS: A decision-tree model was developed to determine the cost-effective-
ness of voriconazole in patients with probable or confirmed IPA, using a time ho-
rizon of 12 weeks. Comparators were: voriconazole (IV 6.6 mg/kg/day) and ampho-
tericin B deoxycholate (1mg/kg/day) administered for 10 days at the end of which
was decided if they needed to switch to oral therapy (voriconazole VO 400mg/day)
or to another drug (caspofungin 50mg/day). Clinical efficacy was obtained through
a systematic literature review of published clinical trials. Medical costs were gath-
ered from Colombian price manual SOAT; drug costs were retrieved from official
report SISMED and by Law 3470/2011 in Colombia. Costs considered were: drugs,
hospitalization, andmedicalmanage associatedwith adverse events (liver enzyme
abnormalities or renal failure). Effectiveness measure was life-years gained (LYG).
Incremental Cost-Effectiveness ratio (ICER) and sensitivity analyses for key vari-
ables were performed to test model robustness. Results were expressed in 2011
US$. RESULTS: The model reveal an increase of LYGs with voriconazole against
amphotericin B (1.61 vs. 0.64), and higher costs per patient with voriconazole
(US$5,225) compared to amphotericin B (US$4,577), with an ICER of US$968.69/LYG.
Likewise, amphotericin B exhibited higher likelihood of developing nephrotoxicity
(0.1780 vs. 0.481) and treatment failure (0.4660 vs. 0.3221) in comparison to
voriconazole. CONCLUSIONS: The economic assessment indicates that voricona-
zole was the cost-effectiveness therapy for the treatment of immunocompromised
Colombian adult patients with IPA.
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OBJECTIVES: Portuguese guidelines for treatment of antiretroviral (ARV) therapy-
naïve HIV-patients include the use of combination ARV regimens with  three
drugs, such as two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
and a ritonavir-boosted protease inhibitor. Ritonavir-boosted atazanavir (ATV/r)
and lopinavir (LPV/r) are among recommendedfirst-line therapies. This study com-
pared lifetime clinical benefits and cost-effectiveness of ARV therapywith ATV/r or
LPV/r in treatment-naïve HIV patients at different baseline CD4 levels from the
Portuguese National Healthcare System perspective. METHODS: A microsimula-
tion model compared the average patient population of the CASTLE trial, treated
with either ATV/r or LPV/r (median CD4 level 205 cells/m3), with the subgroup of
patients with a CD4 level of 200 cells/m3 when enrolled in the trial. Virological
responsewasmodelled as reduction in viral-load (50 copies/ml), impacting CD4
cell count as well as risk of AIDS Defining Events (ADEs) and cardiovascular events.
Both treatment-specific adverse events (AE) and long-term toxicities were in-
cluded. Relative drug efficacy and AEs were based on data from the CASTLE study;
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